- Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). Treasure Island (FL): StatPearls; 2022.
- Christie A, Mbaeyi SA, Walensky RP. CDC Interim Recommendations for Fully Vaccinated People: An Important First Step. JAMA. 2021;325:1501-2. doi: 10.1001/jama.2021.4367. PubMed PMID: 33688914.
- Delang L, Neyts J. Medical treatment options for COVID-19. Eur Heart J Acute Cardiovasc Care. 2020;9:209-14. doi: 10.1177/2048872620922790. PubMed PMID: 32363880; PubMed Central PMCID: PMCPMC7235633.
- Imran M, Kumar Arora M, Asdaq SMB, Khan SA, Alaqel SI, Alshammari MK, et al. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. Molecules. 2021;26. doi: 10.3390/molecules26195795. PubMed PMID: 34641339; PubMed Central PMCID: PMCPMC8510125.
- Hashemian SMR, Pourhanifeh MH, Hamblin MR, Shahrzad MK, Mirzaei H. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother. 2022;146:112517. doi: 10.1016/j.biopha.2021.112517. PubMed PMID: 34902743; PubMed Central PMCID: PMCPMC8654603.
- Zhao J, Guo S, Yi D, Li Q, Ma L, Zhang Y, et al. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res. 2021;190:105078. doi: 10.1016/j.antiviral.2021.105078. PubMed PMID: 33894278; PubMed Central PMCID: PMCPMC8059291.
- Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clin Infect Dis. 2023;76:165-71. doi: 10.1093/cid/ciac180. PubMed PMID: 35245942; PubMed Central PMCID: PMCPMC9383515.
- Kabinger F, Stiller C, Schmitzova J, Dienemann C, Kokic G, Hillen HS, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:740-6. doi: 10.1038/s41594-021-00651-0. PubMed PMID: 34381216; PubMed Central PMCID: PMCPMC8437801.
- Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386:509-20. doi: 10.1056/NEJMoa2116044. PubMed PMID: 34914868; PubMed Central PMCID: PMCPMC8693688.
- Wang Z, Yang L, Song XQ. Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. Front Immunol. 2022;13:1015355. doi: 10.3389/fimmu.2022.1015355. PubMed PMID: 36561747; PubMed Central PMCID: PMCPMC9763260.
- Xie Y, Yin W, Zhang Y, Shang W, Wang Z, Luan X, et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 2021;31:1212-4. doi: 10.1038/s41422-021-00570-1. PubMed PMID: 34584244; PubMed Central PMCID: PMCPMC8477624.
- Cox RM, Wolf JD, Lieber CM, Sourimant J, Lin MJ, Babusis D, et al. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat Commun. 2021;12:6415. doi: 10.1038/s41467-021-26760-4. PubMed PMID: 34741049; PubMed Central PMCID: PMCPMC8571282.
- Schafer A, Martinez DR, Won JJ, Meganck RM, Moreira FR, Brown AJ, et al. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci Transl Med. 2022;14:3410. doi: 10.1126/scitranslmed.abm3410. PubMed PMID: 35315683; PubMed Central PMCID: PMCPMC8995034.
- Qian HJ, Wang Y, Zhang MQ, Xie YC, Wu QQ, Liang LY, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin. 2022;43:3130-8. doi: 10.1038/s41401-022-00895-6. PubMed PMID: 35296780; PubMed Central PMCID: PMCPMC8924727.
- Shen Y, Ai J, Lin N, Zhang H, Li Y, Wang H, et al. An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerg Microbes Infect. 2022;11:1518-23. doi: 10.1080/22221751.2022.2078230. PubMed PMID: 35579892; PubMed Central PMCID: PMCPMC9176639.
- Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. 2023;388:406-17. doi: 10.1056/NEJMoa2208822. PubMed PMID: 36577095; PubMed Central PMCID: PMCPMC9812289.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. PubMed PMID: 33782057; PubMed Central PMCID: PMCPMC8005924.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. doi: 10.1136/bmj.39489.470347.AD. PubMed PMID: 18436948; PubMed Central PMCID: PMCPMC2335261.
- Fischer WA, 2nd, Eron JJ, Jr., Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14:eabl7430. doi: 10.1126/scitranslmed.abl7430. PubMed PMID: 34941423; PubMed Central PMCID: PMCPMC10763622.
- Johnson MG, Strizki JM, Brown ML, Wan H, Shamsuddin HH, Ramgopal M, et al. Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 2023;51:1273-84. doi: 10.1007/s15010-022-01959-9. PubMed PMID: 36648627; PubMed Central PMCID: PMCPMC9844162.
- Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, Lyon R, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021;76:3286-95. doi: 10.1093/jac/dkab318. PubMed PMID: 34450619; PubMed Central PMCID: PMCPMC8598307.
- Khoo SH, FitzGerald R, Saunders G, Middleton C, Ahmad S, Edwards CJ, et al. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Infect Dis. 2023;23:183-95. doi: 10.1016/S1473-3099(22)00644-2. PubMed PMID: 36272432; PubMed Central PMCID: PMCPMC9662684
- Sinha S, N K, Suram VK, Chary SS, Naik S, Singh VB, et al. Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India. Cureus. 2022;14:e31508. doi: 10.7759/cureus.31508. PubMed PMID: 36532902; PubMed Central PMCID: PMCPMC9751243.
- Zou R, Peng L, Shu D, Zhao L, Lan J, Tan G, et al. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial. Front Pharmacol. 2022;13:939573. doi: 10.3389/fphar.2022.939573. PubMed PMID: 35784723; PubMed Central PMCID: PMCPMC9248931.
- Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281-93. doi: 10.1016/S0140-6736(22)02597-1. PubMed PMID: 36566761; PubMed Central PMCID: PMCPMC9779781
- Arribas JR, Bhagani S, Lobo SM, Khaertynova I, Mateu L, Fishchuk R, et al. Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. NEJM Evid. 2022;1:EVIDoa2100044. doi: 10.1056/EVIDoa2100044. PubMed PMID: 38319178.
- Bruno G, Giotta M, Perelli S, De Vita G, Bartolomeo N, Buccoliero GB. Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19. Viruses. 2022;14. doi: 10.3390/v14112514. PubMed PMID: 36423123; PubMed Central PMCID: PMCPMC9695104.
- Bruno G, Perelli S, Giotta M, Bartolomeo N, De Vita G, Buccoliero GB. Efficacy and safety of oral antivirals in individuals aged 80 years or older with mild-to-moderate COVID-19: preliminary report from an Italian Prescriber Center. Infez Med. 2022;30:547-54. doi: 10.53854/liim-3004-9. PubMed PMID: 36482949; PubMed Central PMCID: PMCPMC9715007.
- Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F, et al. Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience. Infect Dis Ther. 2023;12:257-71. doi: 10.1007/s40121-022-00729-2. PubMed PMID: 36441485; PubMed Central PMCID: PMCPMC9707131.
- Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med. 2022;54:516-23. doi: 10.1080/07853890.2022.2034936. PubMed PMID: 35118917; PubMed Central PMCID: PMCPMC8820829.
- Amani B, Zareei S, Amani B. Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19. Br J Clin Pharmacol. 2022;88:4403-11. doi: 10.1111/bcp.15449. PubMed PMID: 35762036; PubMed Central PMCID: PMCPMC9349444.
- Faust JS, Kumar A, Shah J, Khadke S, Dani SS, Ganatra S, et al. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years. Clin Infect Dis. 2023;77:1257-64. doi: 10.1093/cid/ciad400. PubMed PMID: 37387690.
- Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis. J Med Virol. 2023;95:e28441. doi: 10.1002/jmv.28441. PubMed PMID: 36576379; PubMed Central PMCID: PMCPMC9880713.
- Cheema HA, Jafar U, Sohail A, Shahid A, Sahra S, Ehsan M, et al. Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2023;95:e28471. doi: 10.1002/jmv.28471. PubMed PMID: 36606609.
- Zheng Q, Ma P, Wang M, Cheng Y, Zhou M, Ye L, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect. 2023;86:66-117. doi: 10.1016/j.jinf.2022.09.027. PubMed PMID: 36191676; PubMed Central PMCID: PMCPMC9523907.
|